Finally, TVB- 2640 compound is one of the first bioavailable fatty acid synthase (FASN) inhibitor to enter clinical trials for breast, colon, and astrocytic tumors, in combination with chemotherapy with the aim of enhancing clinical responses and prolonging stable disease times (NIH). The gene discussed is FASN; the disease is astrocytic tumor.